Viracta Therapeutics (VIRX) PT Lowered to $4 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St indexes climb after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Viracta Therapeutics, Inc. (VIRX) Tops Q2 EPS by 12c
August 14, 2024 8:04 AM EDTViracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.
... MoreViracta Therapeutics (VIRX) Reports Positive Data from the Phase 2 NAVAL-1 Trial
August 14, 2024 7:00 AM EDTViracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported positive Phase 2 NAVAL-1 trial results from Stages 1 and 2 of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort. Additionally, the Company received productive feedback from its meeting with the U.S. Food and Drug Administration (FDA), providing clarity on the potential regulatory path to initial registration of Nana-val in patients with R/R EBV+ PTCL. Based on FDAs feedback, Viracta plans to begin... More
